The vaccine used in this trial, known as AHEAD-MERIT (BNT113-01), will help the immune system recognise and kill cancer cells ...

German drugmaker CureVac and GSK reached an agreement with BioNTech and Pfizer on Thursday to resolve a years-long patent ...

In Danes over age 65, the vaccine effectiveness of the JN.1-based mRNA boosters reached 70-85% against COVID-related hospitalization and 76-96% against COVID-associated death. Despite the shift away ...

CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent dispute with Pfizer and ...

People with head and neck cancer in England will be fast-tracked on to a clinical trial for a “potentially transformative” vaccine under new NHS plans. The first patients have received the jab, which ...

Messenger RNA vaccines, or mRNA, differ from traditional ones. Instead of growing a virus and weakening it to allow the body to engage its natural defenses, mRNA vaccines use pieces of genetic code to ...

A research project at Emory University is among the 22 grants and contracts that are being cancelled as the U.S. Department ...

In justifying the government's termination of $500 million in funding for mRNA vaccine projects, Health and Human Services ...

There have been no changes to the licensing and royalty agreements related to mRNA research that have netted the university ...

The move drew sharp criticism from medical and health experts. “Scrapping the fastest platform we have is a reckless move ...

Warning comes after HHS Secretary Robert F. Kennedy Jr. announced cuts of nearly $500m in funding for mRNA vaccine projects, ...

Modern science emerged precisely to deal with the way everything can be manipulated – and scepticism over ‘facts’ goes all ...